Enhance Your Recruitment & Retention Strategy For Rare Kidney Disease Trials

By Dr. Graham J. Birrell, Vice President and Therapeutic Area Head, Renal & Cardiometabolic Center of Excellence, and Dr. Manthinda Hettiarachchi, Senior Director and Operational Strategy Head, Renal & Cardiometabolic Center of Excellence

Thanks to rapid breakthroughs in genetic understanding and a growing prioritization of orphan drugs, the number of rare kidney disease clinical trials are steadily increasing. Though treatment possibilities are growing, these trials face a number of challenges, including low patient volumes, high patient burden, a competitive trial landscape, fragmented clinical networks, limited epidemiology data, and complex protocol designs.

For a rare kidney disease trial to find success, sponsors must prioritize incorporating the perspectives of key opinion leaders in the field, patient advocacy organizations, and patients themselves to build more effective protocols and ensure robust recruitment and retention. It is also critical to identify a CRO that has the renal disease expertise to support your trial’s unique demands. Download the full article to explore strategies for establishing more accessible, scientifically sound, and strategic rare kidney disease trials.